NCT03669549 - Nevanimibe HCl for the Treatment of Classic CAH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

June 3, 2020

Study Completion Date

July 12, 2020

Conditions

Congenital Adrenal Hyperplasia

Interventions

DRUG

Nevanimibe hydrochloride

During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.

Trial Locations (11)

14051-140

University of Ribeirão Preto, Medicine Faculty (Faculdade de Medicina) of Ribeirão Preto, Ribeirão Preto

04037-002

Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo

05403-900

Hospital das Clínicas da FMUSP - Prédio do Instituto Central, São Paulo

Unknown

Institute of Endocrinology, Prague

Hospital Pitié-Salpetrière, Paris

Bnai Zion Medical Center, Haifa

Beilinson Hospital, Petah Tikva

Tel-Aviv-Sourasky Medical Center, Tel Aviv

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario Virgen del Rocío, Seville

University Hospital La Fe, Valencia